Some of the most advanced tau-targeting trial therapies for Alzheimer’s disease (AD) are based on use of antibodies intended to bind and neutralise extracellular tau species capable of propagating tau pathology. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.